U.S. Electrocardiogram (ECG) Devices Market - By Product, By Lead Type, By Portability, By End Use - Global Forecast, 2025 - 2034

U.S. Electrocardiogram Devices Market Size

The U.S. electrocardiogram devices market size was valued at USD 2.4 billion in 2024 and is projected to exhibit 6.1% CAGR from 2025-2034. The U.S. ECG device market is witnessing rapid growth mainly due to the soaring incidence of cardiovascular diseases (CVDs) such as arrhythmias, coronary artery disease, and myocardial infraction which have been, and remain, a leading cause of death across the country, and presents a long-standing public health problem.
 

For instance, the New York State Department of Health estimates that approximately 695,000 individuals die from heart disease annually in the U.S., which is about 1 in every 5 deaths nationwide. This gives us an idea of how much we can rely on effective management via timely diagnosis and regular surveillance in care and prevention for cardiovascular health.
 

Additionally, ECG devices are vital equipment for healthcare providers, as they allow for early detection and surveillance of cardiac impairments. The steady increase of ECG technology being utilized by hospitals, emergency departments, and outpatient facilities, validates that the health system within the U.S. is making a transition towards preventive medicine and precision medicine. Moreover, the ECG device market development is supported due to rapid growth in the elderly population pushing demand for ECG monitoring solutions, as seniors are the most at risk for chronic cardiac conditions like atrial fibrillation and heart failure and thus, likely sustain frequent or continuous needs for cardiac monitoring.
 

Both wearable ECG and home-based ECG have been increasingly involved in chronic illness management in older adults.  Real time health measures suggest that these new devices can monitor health status, reduce hospitalizations, while improving quality of life for older adults. Furthermore, the advances in technology have ushered the ECG landscape into a time of innovation and evolution in accessibility. Standard ECG systems are being revolutionized into intelligent, connected systems, with innovations such as artificial intelligence (AI), smartphones, wireless, and cloud data sharing in development. All these innovations have the potential to enhance accuracy and drive remote patient monitoring to a scalable level allowing clinicians to act faster and more intelligently.
 

U.S. Electrocardiogram Devices Market Trends

• The market is witnessing a significant shift towards artificial intelligence (AI) in the future of ECG diagnostics. New ECG devices incorporate advanced AI algorithms for detecting ischemia, arrhythmias or heart failure - all with high specificity. These AI applications enhance the accuracy of ECG diagnostics and alleviate the work burden from clinicians and/or allied technology staff.
   
• Furthermore, as the FDA continues to approve AI-enabled or AI-enhanced products, there will be widespread adoption of these effective ECG devices, especially relevant in primary care and low-resource settings, where skilled personnel may not be available. AI applications are going to be an important strategy to accomplish earlier interventions and efficient triage of patients.
   
• A case in point is Powerful Medical receiving FDA Breakthrough Device Designation for its PMcardio STEMI AI ECG model in March 2025, which provides fast and accurate diagnosis of life-threatening cardiac events. This milestone represents significant advancement toward a fully automated and high-performance cardiovascular screening.
   
• At the same time, the shift toward home- or community-based and decentralized care will continue to drive demand for portable and wearable ECG monitors that provide continuous and real-time heart monitoring outside clinical environments. This has direct implications in chronic disease management and supporting aging.
   

U.S. Electrocardiogram Devices Market Analysis

Based on product, the market is bifurcated into diagnostic ECG machines and monitoring ECG machines. The diagnostic ECG device segment is further sub-segmented into resting ECG and stress ECG. Additionally, the monitoring devices segment is further sub-segmented into Holter monitoring, ECG telemetry monitoring/event monitoring, implantable cardiac monitors, and other monitoring ECG devices. The diagnostic ECG machines segment dominated the market with the largest revenue share of 62.7% in 2024.
 

• Modern diagnostic ECG devices are fundamental components of cardiac care justification by providing clinicians access to identify a range of heart disturbances, such as arrhythmias, myocardial infarctions, and other cardiac disorders.
   
• Diagnostic ECG devices are especially significant in the emergency room and primary care settings, where the identification of potential cardiac disorders early in the patient treatment can affect patient survival and subsequently patient treatment outcomes.
   
• The emerging demand for these technologies is in part due to the heavy implications of cardiovascular disease in the U.S. Cardiovascular disease is still the number one cause of death in the U.S. On average, coronary heart disease accounted for approximately 371,506 deaths in the U.S. in 2022 according to the Centers for Disease Control and Prevention (CDC).In short, ECG machines are vital diagnostic devices that create a quick, data-driven clinical decision-making process.
   
• Therefore, the aforementioned factors are expected to significantly boost segment growth over the forecast period.
   

Based on lead type, the U.S. electrocardiogram devices market is segmented into 12 lead type, 6 lead type, single lead type, 3 lead type, and other lead types. The 12 lead type segment dominated the market with the largest revenue of USD 1.6 billion in 2024 and is expected to grow at a significant CAGR over the forecast period.
 

• 12-lead ECG devices are typically considered the best available cardiac diagnostic tools in the U.S. healthcare system. 12-lead ECGs provide the most comprehensive view of the heart's electrical activity to evaluate multiple electrical signals from various anatomical views.
   
• Therefore, cardiologists and emergency room physicians are able to obtain diagnostic help in interpreting multiple cardiovascular conditions and issues that require immediate medical intervention, including myocardial infarction, ischemia, bundle branch blocks, hypertrophy, and complex arrhythmias. Information obtained from 12-lead ECGs create the foundation for clinical decision-making in hospitals, emergency departments, cardiac units, and specialty clinics.
   
• 12-lead ECGs are used extensively in the U.S. due to the high prevalence of coronary artery disease (CAD) and acute cardiac events. According to the National Institute of Health, CAD remains the number one cause of death across the country, contributing to approximately 610,000 deaths annually, or one in four deaths.
   
• Under these circumstances, expedient and accurate interpretation of ECGs are oftentimes essential for deciding therapeutic interventions such as thrombolysis, angioplasty, when chronic revascularization is no longer an option; those decisions could be of primary importance for patient care.
   
• Therefore, the aforementioned factors are expected to significantly boost segment growth over the forecast period.
   

Based on portability, the U.S. electrocardiogram devices market is bifurcated into portable devices and non-portable devices. The portable devices segment dominated the market with the largest revenue of USD 1.4 billion in 2024.
 

• Portable electrocardiogram devices (ECGs) are becoming increasingly popular in the U.S. healthcare market as the shift to decentralization and patient-centered care is underway.
   
• They give flexibility, ease of use, and the ability to monitor cardiac activity in a timely fashion beyond the traditional clinical environment, supporting both new and old uses in chronic disease management, preventive care, and emergency situations.
   
• Portable ECGs have become essential diagnostic tool due to the U.S. healthcare system's increased focus on an outpatient model and can perform cardiac diagnostics outside of the hospital setting. They promote decreased hospital visits for patients on cardiac management plan, and the possibility of performing cardiac assessments leads to timely care intervention.
   
• Therefore, the aforementioned factors are expected to significantly boost segment growth over the forecast period.

Based on end use, the U.S. electrocardiogram devices market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, home care settings, and other end users. The hospitals and clinics segment dominated the market with the largest revenue of USD 917.9 million in 2024.
 

• ECG devices continue to fulfill fundamental diagnostic requirements in hospitals and clinics across the U.S. where timely and accurate assessments are needed in management of acute and chronic cardiovascular concerns.  The incorporation of these systems into care delivery in emergency rooms, inpatient units, outpatient clinics and surgical areas along with the experience of real-time assessments, diagnosis, and treatment decisions deepens their usefulness.
   
• In emergency departments and critical unit settings, ECG devices provide real-time assessment in determining life-threatening events related to cardiac concerns such as cardiac arrests, arrhythmias, and myocardial infarctions.  The American Heart Association states there are345,000 deaths annually due to cardiac arrest in the USA.  Immediate assessments and accurate diagnostic capability is critical and ECG devices improve triaging and required interventions such as thrombolysis or angioplasty.  These are the only devices fully integrated into acute care workflows.
   
• While hospitals and surgical centers use ECG systems prior to surgery to assess and evaluate the risks of surgical patients, monitoring the cardiac status of all surgical patients post-operatively has become even more critical.  Cardiac complications of surgery continue to be a high risk for surgical patients, especially those with comorbidities such as diabetes or hypertension.
   
• Therefore, the aforementioned factors are expected to significantly boost segment growth over the forecast period.

The South Atlantic electrocardiogram devices market was valued at USD 476.5 million in 2024 and is expected to grow at a CAGR of 7.1% over the forecast period. The market is driven by the increasing aging population across the region.
 

The North East market is projected to grow significantly from USD 412.3 million in 2024 to USD 710.6 million by 2034.
 

• The ECG device market in the Northeast region of the United States— New York, New Jersey, Pennsylvania, Massachusetts and Connecticut— is especially relevant due to the aging population, healthy healthcare ecosystem, and existing digital health ecosystem.
   
• For example, in Connecticut persons over 60 years old represent approximately 23 percent of the population (estimated to be around 823,529 individuals in 2024). This age demographic is at higher risk for cardiovascular diseases, such as atrial fibrillation and ischemic heart disease, and related conditions such as heart failure. This had created demand for continuous cardiac monitoring and preventive solutions that offer 24/7 monitoring.
   
• For this reason, the uptake of wearable and home ECG technologies has also occurred rapidly across the Northeast. These modalities support different approaches to address timely abnormality detection, chronic disease short-term case management at home, and the ability for a timely intervention that reduces emergency department visits or hospitalizations for patients who are high-risk or elderly.
   
• Therefore, the aforementioned factors are expected to significantly boost regional growth over the forecast period.
   

The East North Central electrocardiogram devices market was valued at USD 376.3 million in 2024 and is expected to grow at a CAGR of 5.6% over the forecast period.
 

• The East North Central region of the U.S., which includes Illinois, Indiana, Michigan, Ohio, and Wisconsin— represents a highly-populated and industrially developed region with an established healthcare system. Nevertheless, the region experiences a gnawing burden of cardiovascular disease, hypertension, and obesity-related consequences, which drives endless sustained demand for a scalable ECG monitoring capacity.
   
• The CDC indicates that heart disease was the leading cause of death in Michigan (27,266 deaths) and Ohio (30,041 deaths) in 2022, underscoring the necessity for regional access to cardiac diagnostics and preventive care.
   
• Field premier metropolitan areas, such as Chicago, Detroit, Cleveland, and Indianapolis—are anchored by major academic hospitals, cardiac specialty systems and research universities that document advanced cardiovascular ECG systems to conduct multi-lead diagnostics, ECG stress tests, electrophysiology services, and electronic health record (EHR) workflows which promise tailored cardiac care.
   

The Pacific Central electrocardiogram devices market is expected to experience significant and promising growth from 2025 to 2034.
 

• The Pacific Central region of the U.S. states, which includes California, Oregon, Washington, Alaska, and Hawaii, was valued at USD 324.4 million in 2024 and is estimated to grow with a CAGR of 6.8% throughout the forecast period.
   
• Heart disease burden is increasing in the PACCENTRAL region primarily because of the aging population and lifestyle-related risks, with heart disease rates highest in California.
   
• According to the California Department of Public Health, heart disease related deaths for 2022 only was 66,340 which points to the need for supportive ECG monitoring infrastructure to support preventive screening, early detection, and long-term cardiac management.
   
• California has an extensive network of academic medical centers, outpatient diagnostics laboratories, and ambulatory facilities which have paved the way for early adoption of multi-lead ECG systems, AI-enabled platforms for care, and electrophysiological diagnostics. These technologies provide advantages compared to standard systems and improve capability for rhythm assessment, stress testing, efficacy in cardiac care for personalized medicine.
   
• Hence, the above-mentioned factors are propelling the market growth in the region.
   

U.S. Electrocardiogram Devices Market Share

The U market has a dynamic mix of international and domestic players providing innovative solutions to meet the growing demand for advanced treatments for the growing patient population. Companies such as GE HealthCare Technologies, Koninklijke Phillips, Baxter International, OSI Systems, and Schiller are some of the dominant competitors in the market accounting for a combined market share of approximately 60%.
 

Competition in this area arises from continuous technological developments and the ability to offer customized solutions. In developing nations, due to the priority given to cost, multinational companies are squeezed to offer electrocardiogram (ECG) devices that are both affordable and of quality. Domestic manufacturers take advantage of this demand by providing cost effective alternatives, which make multinationals alter their price strategy while maintaining the safety, ruggedness, and regulatory acceptability of the products.
 

U.S. Electrocardiogram Devices Market Companies

Some of the eminent market participants operating in the Electrocardiogram devices industry include:

• AliveCor
• Allengers
• Baxter International
• Bionet Co.
• Biotricity
• BIOTRONIK
• Boston Scientific
• BPL Medical Technologies
• Cardioline
• Fukuda Denshi
• GE HealthCare Technologies
• Koninklijke Philips
• Medtronic
• Mindray
• Nihon Kohden
• OSI Systems
• Schiller

• AliveCor's competitive advantage is distanced in an entirely different direction, with its novel utilization of AI-enabled, smart-phone connected ECG/ECG technology intended for consumer utilization at an unrivaled clinical grade. Its KardiaMobile devices cleared by the FDA provide the ability for patients to have real-time cardiac monitoring from their homes.
   
• GE HealthCare makes value in the U.S. ECG devices market through high-fidelity ECG devices with hospital-grade systems that are interoperable with their enterprise imaging and clinical information systems (interoperability). GE combines effective data capture with diagnostic and inference algorithms that are efficient and fundamentally reliable to scale through large health networks.
   
• Medtronic differentiates itself in the U.S. ECG devices competitive market with its full portfolio of implantable and wearable cardiac monitoring options, including long-term insertable cardiac monitors (ICMs) like the Reveal LINQ system. The Reveal LINQ system allows long-term, continuous, remote ECG monitoring supported by the CareLink network so that data is automatically transmitted to the physician.
   

The U.S. electrocardiogram devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

By Product

• Diagnostics ECG machines
  • Resting ECG
  • Stress ECG 
• Monitoring ECG devices
  • Holter monitoring
  • ECG telemetry monitoring/Event monitoring
  • Implantable cardiac monitors
  • Other monitoring ECG devices

By Lead Type

• 12 lead type
• 6 lead type
• Single lead type
• 3 lead type
• Other lead types

By Portability

• Portable device
• Non-portable device

By End Use

• Hospitals and clinics
• Ambulatory surgical centers
• Diagnostic centers
• Home care settings
• Other end use

The above information is provided for the following regions:

• South Atlantic
• North East
• East North Central
• Pacific Central
• West South Central
• West North Central
• Mountain States
• East South Central